Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 37,647 shares of the biopharmaceutical company's stock after acquiring an additional 7,928 shares during the period. Concurrent Investment Advisors LLC's holdings in Gilead Sciences were worth $4,218,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences during the 1st quarter valued at about $25,000. Goodman Advisory Group LLC purchased a new position in Gilead Sciences during the 1st quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 216 shares during the period. Lee Danner & Bass Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $41,000. Finally, Investment Research & Advisory Group Inc. boosted its stake in shares of Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the sale, the chief executive officer owned 615,725 shares of the company's stock, valued at $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the sale, the insider directly owned 120,168 shares in the company, valued at $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,500 shares of company stock valued at $6,340,745. Insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on GILD shares. Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Price Performance

Shares of GILD traded down $0.42 during trading hours on Monday, reaching $111.33. The company had a trading volume of 911,644 shares, compared to its average volume of 7,681,092. The firm has a 50 day simple moving average of $107.02 and a 200-day simple moving average of $104.11. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The company has a market capitalization of $138.48 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $66.34 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.32) EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.